Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12587111 | 0.80 | TTR (0.36) | TTRALBMEN1KMT2A | |
| SCHEMBL27908 | 0.80 | ENPP2 (0.61) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL15602898 | 0.80 | ENPP2 (0.61) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL10251503 | 0.75 | TTR (0.39) | TTRALBMEN1KMT2A | |
| 1,3-Propanediol SCHEMBL29185453 | 0.73 | ENPP2 (0.50) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL29952148 | 0.72 | ENPP2 (0.53) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL12271100 | 0.71 | ENPP2 (0.57) | ENPP2MEN1KMT2AP4HB | |
| SCHEMBL12247412 | 0.71 | ENPP2 (0.38) | ENPP2TTR | |
| SCHEMBL3326314 | 0.71 | ENPP2 (0.52) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL874242 | 0.71 | ENPP2 (0.52) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9627626-B2 | Compounds for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130285036-A1 | COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | ENPP2 642/4885TTR 1344/4885ALB 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.